Study Subject Enrollment Sample Clauses

Study Subject Enrollment. Institution and/or Investigator shall use its reasonable goodfaith efforts to enroll Study Subjects who meet the requirements of the Protocol or as otherwise 2. Zařazování subjektů do studie. Zdravotnické zařízení a/nebo zkoušející vyvinouv dobré víře přiměřené úsilí a zařadí do studie subjekty, které splňují požadavky protokolu nebo set forth in the written instructions provided by the Sponsor. After the f th) Study Subject is randomized to the Study at the Institution, Institution or Investigator must seek Sponsor approval prior to initiating additional screening activities to enroll more Study Subjects after the 4th Study Subject. Sponsor approval must be documented in writing via email or other written approval. Payments for all Subjects enrolled by Institution with Sponsor written approval, are subject to the terms of this Agreement, payment terms and the Study Budget. zařízení, musí zdravotnické zařízení nebo zkoušející získat souhlas zadavatele ▇▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ screening pro zařazení dalších subjektů studie po . subjektu studie. Souhlas zadavatele musí být doložen písemně ve formě e-mailu nebo jiného písemného souhlasu. Platby pro všechny subjekty studie zařazené zdravotnickým zařízením s písemným souhlasem zadavatele podléhají podmínkám této smlouvy, platebním podmínkám a rozpočtu studie.
View SourceView Similar (2)
Study Subject Enrollment. Institution 2.
View SourceView Similar (2)
Study Subject Enrollment. Institution and/or Investigator shall use its reasonable good faith efforts to enroll Study Subjects who meet the requirements of the Protocol or as otherwise set forth in the written instructions provided by the Sponsor. After the fourth (4th) Study Subject is randomized to the Study at the Institution, Institution or Investigator must seek Sponsor approval prior to initiating additional screening activities to enroll more Study Subjects after the 4th Study Subject. Sponsor approval must be documented in writing via email or other written approval. Payments for all Subjects enrolled by Institution with sponsor written approval are subject to the terms of this Agreement, payment terms and the Study Budget.
View Source
Study Subject Enrollment. Upon receipt of any notice of termination or suspension, University and Principal Investigator agree that no additional Study subjects will be enrolled in the Study. Any Study subjects already enrolled in the Study will be phased-out as deemed appropriate by Company and Principal Investigator. Company shall give University a minimum of fourteen (14) days notice before closing enrollment so University does not incur unnecessary costs or disappoint potential Subjects that are in the recruiting process.
View Source
Study Subject Enrollment. Institution has agreed that Principal Investigator will enroll Study Subjects in the Study in accordance with the Protocol and in accordance with IEC and/or RA approval. Sponsor may discontinue Study Subject enrollment if the total enrollment needed for a multi-center Study has been achieved, if applicable.
View Source
Study Subject Enrollment hodnocení dodají Instituci dostatečná množství Hodnoceného přípravku k provádění Klinického hodnocení dle podmínek v Protokolu.
View Source
Study Subject Enrollment. Institution and/or Investigator shall use its reasonable good faith efforts to enroll Study Subjects who meet 2. Zařazování subjektů do studie. Zdravotnické zařízení a/nebo zkoušející vyvinou v dobré víře přiměřené úsilí a zařadí do studie
View Source
Study Subject Enrollment. Institution agrees to enroll qualified Study Subjects in the Study, in accordance with the Protocol and in accordance with IEC and/or RA approval. A qualified Study Subject is one whom meets all the Protocol criteria for participation in the Study. Principal Investigator announces the inclusion of the Study Subject to the Study specifying the decision number of the Study and the date of inclusion of the Study Subject in the Study to the health insurance company conducting the Public Health Insurance of Study Subject immediately after inclusion of the Study Subject to the Study in accordance with the provisions of Section 26 of No. 576/2004 Coll.. Sponsor may discontinue Study Subject enrollment if the total enrollment needed for a multi-center Study has been achieved or before Institution has enrolled the minimum number of Study Subjects. Protocol does not require hospitalization during the course of the Study.
View Source
Study Subject Enrollment. Institution has agreed to enroll Study Subjects in the Study in accordance with the Protocol and in accordance with IEC and Competent Authority approvals. Sponsor may discontinue Study Subject enrollment if the total enrollment needed for a multi-center Study has been achieved, if applicable. Protocol does not require hospitalization during the course of the Study. Informed Consent. Institution shall ensure that the Informed Consent Form (“ICF”), which must comply with Applicable Law, as approved by Sponsor, Sponsor’s Designee (Syneos Health), the IEC and, if required, the Competent Authority, is properly executed by each Study Subject before (i) such Study Subject is enrolled in the Study; and (ii) any personal data of such Study Subject is processed.
View Source

Related to Study Subject Enrollment

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Random Drug Testing All employees covered by this Agreement shall be subject to random drug testing in accordance with Appendix D.

  • Study Population ‌ Infants who underwent creation of an enterostomy receiving postoperative care and awaiting enterostomy closure: to be assessed for eligibility: n = 201 to be assigned to the study: n = 106 to be analysed: n = 106 Duration of intervention per patient of the intervention group: 6 weeks between enterostomy creation and enterostomy closure Follow-up per patient: 3 months, 6 months and 12 months post enterostomy closure, following enterostomy closure (12-month follow-up only applicable for patients that are recruited early enough to complete this follow-up within the 48 month of overall study duration).

  • Medicaid Enrollment Treatment Grantees shall enroll as a provider with Texas Medicaid and Healthcare Partnership (TMHP) and all Medicaid Managed Care organizations in Grantee’s service region within the first quarter of this procurement term and maintain through the procurement term.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.